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ABSTRACT 
Epidemiological studies show that maternal immune activation (MIA) during pregnancy 
is a risk factor for autism. However, mechanisms for how MIA affects brain development 
and behaviors in offspring remain poorly described. To determine whether placental 
interleukin-6 (IL-6) signaling is required for mediating MIA on the offspring, we 
generated mice with restricted deletion of the receptor for IL-6 (IL-6Rα) in placental 
trophoblasts (Cyp19-Cre+;Il6rafl/fl), and tested offspring of Cyp19-Cre+;Il6rafl/fl mothers 
for immunological, pathological and behavioral abnormalities following induction of 
MIA. We reveal that MIA results in acute inflammatory responses in the fetal brain. Lack 
of IL-6 signaling in trophoblasts effectively blocks MIA-induced inflammatory responses 
in the placenta and the fetal brain. Furthermore, behavioral abnormalities and cerebellar 
neuropathologies observed in MIA control offspring are prevented in Cyp19-
Cre+;Il6rafl/fl offspring. Our results demonstrate that IL-6 activation in placenta is 
required for relaying inflammatory signals to the fetal brain and impacting behaviors and 
neuropathologies relevant to neurodevelopmental disease. 
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1. INTRODUCTION 
Autism spectrum disorder (ASD) is a range of complex neurodevelopmental disorders, 
characterized by difficulties in social communication, and repetitive and stereotyped 
behaviors (Association, 2013). To date, the prevalence for ASD in the United States is 
one in 68 children (Investigators, 2014) and diagnoses worldwide are 62 per 10,000 
people (Elsabbagh et al., 2012). Monozygotic twins studies indicate the concordance rate 
for ASD ranges between 60 and 91% (Ronald and Hoekstra, 2011), which suggests both 
genetic and non-genetic factors (e.g. environment) could contribute to the etiology of 
ASD.  
Epidemiological studies suggest that maternal infection is a principal non-genetic risk 
factor for ASD (Brown, 2012). Analyses of large cohorts of ASD patients found that 
inpatient diagnosis of severe infection during pregnancy are associated with increased 
ASD risk (Atladottir et al., 2010; Lee et al., 2014). The diversity of infections and the 
observation that many are not transmitted to the fetus (Fatemi et al., 2012; Shi et al., 2005) 
suggest that maternal immune activation (MIA), rather than microbial pathogenesis, is 
responsible for increasing the risk of ASD in the offspring. This emphasis on MIA rather 
than a specific pathogen is supported by animal models that involve injection of non-
pathogenic antigens, such as polyinosinic-polycytidylic acid (poly(I:C))(Boksa, 2010; 
Meyer, 2014). Stimulation of the maternal immune system in these cases causes offspring 
to develop behavioral and neuropathological features of ASD similar to those seen in 
maternal infection (Boksa, 2010; Knuesel et al., 2014; Meyer, 2014). 
The molecular mechanisms underlying abnormal neurodevelopment and behavior in MIA 
are poorly understood, though cytokines appear to be critical (Boksa, 2010; Knuesel et al., 
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2014). The immune dysregulation in MIA offspring persists postnatally (Garay et al., 
2013; Hsiao et al., 2012). MIA causes long-lasting and region specific changes of brain 
cytokines in the offspring that vary based on developmental time point (Garay et al., 
2013). Furthermore, MIA leads to decreases in splenic and mesenteric regulatory T cells 
(Tregs) and increases in interleukin (IL)-6 and IL-17 production in splenic CD4+ T cells 
in adult offspring (Hsiao et al., 2012). IL-6 levels are elevated in fetal brain after MIA 
induction (Connor et al., 2012; Meyer et al., 2006; Wu et al., 2015). Blocking IL-6, but 
not IL-1β or interferon gamma (IFNγ), after induction of MIA in pregnant mice prevents 
behavioral abnormalities in the offspring (Smith et al., 2007). Furthermore, injection of 
recombinant IL-6 alone into mice is sufficient to promote similar behavioral phenotypes 
seen in the MIA model (Hsiao and Patterson, 2011), arguing for a causal role for IL-6 
signaling in this context. The importance of IL-6 in mediating MIA effects on brain and 
behavior in rodents is also supported by the studies shown in human ASD subjects, 
wherein IL-6 is increased in ASD subjects (Ashwood et al., 2011; Li et al., 2009; Masi et 
al., 2014; Vargas et al., 2005; Wei et al., 2011). IL-6 is both necessary and sufficient for 
mediating the effects of MIA on the development of ASD-related behavioral 
abnormalities, suggesting that tracing the pathways of MIA-induced IL-6 signaling may 
reveal novel mechanisms by which maternal insults disrupt fetal neurodevelopment.  
The significance of the placenta in the occurrence of psychiatric disorders has been 
suggested by several studies. The concordance rate of monochorionic twins for 
schizophrenia is 60%, while dichorionic twins is only 10.7% (Davis et al., 1995). 
Examining the histology of the placenta from individuals with ASD reveals that about 3 – 
8-fold increased odds of having trophoblast inclusion in the ASD groups compared to 
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controls (Anderson et al., 2007; Walker et al., 2013). These correlations indicate that the 
uterine environment should also be considered when evaluating potential etiologies for 
psychiatric disorders. 
During infection, increased cytokine levels in the maternal environment might directly 
transmit signals to the fetus through the placenta (Dahlgren et al., 2006; Zaretsky et al., 
2004). Placenta is of fetal origin, juxtaposed against the maternal decidua (D) layer, and 
represents the primary molecular connection between the mother and its developing fetus. 
IL-6 production signaling in the placenta, particularly in the spongiotrophoblast (SP) 
layer, following induction of MIA has been reported (Hsiao and Patterson, 2011). 
Furthermore, the MIA-induced alterations in IL-6 signaling pathways in the placenta, and 
placental hormone production following MIA are prevented upon immune-activation of 
Il6-/- pregnant mice (Hsiao and Patterson, 2011), revealing dependence on placental IL-6. 
Whether placental IL-6 signaling is involved in relaying the detrimental effects of MIA to 
the developing embryo is unknown.  
To understand whether IL-6 signaling in the placenta plays a role in modulating the MIA 
response, we crossed placental trophoblast specific Cre mice (Cyp19-Cre)(Wenzel and 
Leone, 2007) with IL-6Rα loxp-flanked mice (Il6rafl/fl)(McFarland-Mancini et al., 2010) 
to generate trophoblast-specific IL-6Rα knockout mice (Cyp19-Cre+;Il6rafl/fl). The Cyp19 
gene encodes aromatase cytochrome P450 converting androgens to estrogens, which 
plays an important role in uterine and placental growth and differentiation (Furbass et al., 
2008). Different promoter regions of the Cyp19 gene drive its expression into different 
tissues (Rawn and Cross, 2008). The Cyp19-Cre 5912 founder line specifically expresses 
Cre recombinase at placental trophoblast precursor cells during the early stage of 
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embryogenesis and shows minimal expression of Cre recombinase in fetal tissues 
(Wenzel and Leone, 2007), which allows us to examine the functionality of IL-6 in MIA 
model specifically in placental trophoblast population. Herein, we reveal that immune 
activation in the placenta perturbs fetal brain development during gestation, resulting in 
ASD-like behavioral symptoms in offspring. These findings support a growing 
appreciation of environmental risk factors for mental disorders. 
 
2. MATERIALS AND METHODS  
2.1. Mice 
Wild-type C57BL/6N mice were obtained through Caltech’s barrier animal facility 
(originally from Charles River, Wilmington, MA, USA). Il6-/- (002650; B6.129S2-
Il6tm1Kopf/J; Bar Harbor, ME, USA) and Il6rafl/fl mouse lines were obtained from 
Jackson Laboratory (012944; B6;SJL-Il6ratm1.1Drew/J012944; Bar Harbor, ME, USA). 
Cyp19-Cre mouse (5912 line) was obtained by Dr. Gustavo Leone from Ohio State 
University (Wenzel and Leone, 2007). ROSA::LSL-lacZ mouse was kindly provided by 
Dr. David J. Anderson at Caltech. Ate1-/- mice were kindly provided by Dr. Alexander J. 
Varshavsky at Caltech (Brower and Varshavsky, 2009). Mice were maintained at 
Caltech’s barrier animal facility and transferred to Caltech’s Broad animal facility for 
experiments. All mice were group housed (2-5 mice per cage) with a 13 hours light/11 
hours dark cycle (lights on at 06:00) at 21-23°C and 45% relative humidity within a range 
of 30-70% in ventilated cages (Super Mouse 750TM, Lab Products Inc, Seaford, DE, 
USA). Pregnant and lactating mice were fed a mix of half 5053 PicoLab Rodent Diet and 
half 5058 PicoLab Rodent Diet (5053, Lad Diet, St. Louis, MO, USA). All experiments 
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were performed under the approval of the California Institute of Technology Institutional 
Animal Care and Use Committee (IACUC).  
 
2.2. Generation and genotyping of placental trophoblast IL-6Rα knockout mice 
Placental trophoblast IL-6Rα knockout mice, Cyp19-Cre+; Il6rafl/fl, were generated by 
crossing two mouse lines- Il6rafl/fl and Cyp19-Cre (5912 line). To yield a congenic strain 
of Cyp19-Cre+; Il6rafl/fl mice, the Cyp19-Cre+ mouse line was backcrossed to C57BL/6 
for at least 8 generations. After backcrossing, C57BL/6 Cyp19-Cre+ mice were crossed 
with Il6rafl/fl mice, which were originally derived and maintained on C57BL/6J 
background. F1 offspring were Il6rafl/+ and Cyp19-Cre+;Il6rafl/+. These were then 
crossed to yield F2: Il6ra+/+, Il6rafl/+, Il6rafl/fl, Cyp19-Cre+; Il6ra+/+, Cyp19-Cre+; 
Il6rafl/+, and Cyp19-Cre+; Il6rafl/fl. Offspring of Il6rafl/fl and Cyp19-Cre+; Il6rafl/fl 
genotypes were maintained for experiments.  
Mice were weaned at the age of 3 weeks. Then the mice were labeled by ear punch and 
tail snips were collected immediately after weaning. gDNA was extracted using a 
standard DNA extraction protocol. PCR was performed to amplify a fragment of Il6 flox 
allele or wild-type allele. Cre was detected in a separate round of PCR. Primer sequences 
are listed below.  
Il6ra flox allele: Forward 5’-GAA GGA GGA GCT TGA CCT TGG-3’; Reverse: 5’-AAC 
CAT GCC TAT CAT CCT TTG G-3’;  
Cre: Forward 5’-GGC GTT TTC TGA GCA TAC CTG-3’; 5’-CAT TCT CCC ACC GTC 
AGT ACG-3’. 
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For genotyping placentas and fetuses, a piece of tail from the fetus was processed using 
the standard gDNA extraction and PCR procedure, as described above. The genotype of 
the placenta can be determined by the genotype of the corresponding fetus. 
 
2.3. Timed-mating for C57BL/6N wild-type, Il6-/-, and Cyp19-Cre+;Il6afl/fl, mutant mice 
We adopted a trio timed-mating strategy (two female and one male) to minimize the 
number of sires and limit variation. The females were transferred to a clean cage one day 
before the introduced of the male into the cage. Timed-mating pairs were set up in the 
late phase of the light period. Vaginal plugs were checked the following morning. The 
day of vaginal plug presence was considered embryonic day 0.5 (E0.5). Three 
independent mouse lines were used in this study- C57BL/6N wild-type line, Il6-/- mutant 
line, and Cyp19-Cre+;Il6afl/fl mutant line. For the timed-mating of Il6-/- mutant line for 
Luminex cytokine array study, two kinds of breeding pairs were used- wild-type sire x 
Il6-/- dam and Il6-/- sire x wild-type dam. The genotype of offspring yielded from the two 
kinds of breeding pairs is Il6+/-. For the timed-mating of Cyp19-Cre+;Il6afl/fl mutant line, 
the pair we used was Il6rafl/fl sire x Cyp19-Cre+;Il6afl/fl dam. The genotype of offspring 
we yield from the breeding pair included Il6rafl/fl and Cyp19-Cre+;Il6afl/fl. All female mice 
were 8-16 weeks of age, with no prior pregnancies. 
 
2.4. Maternal Immune Activation (MIA) by poly(I:C) 
The induction of MIA is previously described (Chow et al., 2016). Briefly, Potassium salt 
poly(I:C) (P9582; Sigma, St. Louis, MO, USA) was used to induce MIA. 20mg/kg 
poly(I:C) was dissolved in 0.9% sodium chloride (Hospira, Inc, Lake Forest, IL, USA). 
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Either poly(I:C) or saline was intraperitoneally injected into pregnant mice on embryonic 
day 12.5 (E12.5). Poly(I:C) was prepared at 40 mg/ml of the actual weight of poly(I:C) 
powder. 
 
2.5. Harvesting Embryo and placenta at E12.5 from pregnant mice after MIA 
Three hours (hr), 6 hr or 24 hr after poly(I:C) injection, mice were sacrificed by cervical 
dislocation without anesthesia. Placenta and fetal brains were harvested from poly(I:C)- 
and saline-injected pregnant mice, based on prior work in MIA on the placenta (Hsiao 
and Patterson, 2011). Fetal brains were dissected under a stereomicroscope (M5A, Wild 
Heerbrugg, Switzerland). For gene expression analysis, tissues were stored in RNAlater 
(Qiagen, Gaithersburg, MD, USA) at -80o C until later used. For immunohistochemistry, 
fetal brains and placenta were postfixed in 4% paraformaldehyde at 4o C for 30-60 min 
and then cryopreserved in 30% sucrose at room temperature overnight. Tissues were then 
embedded in OCT (Tissue-Tek, Torrance, CA, USA), frozen in 2-methybutane on dry ice 
and stored at -80 o C until used. For LCM, each embryo was immediately embedded in 
OCT and frozen in 2-methybutane on dry ice and stored at -80 degrees until used.  
 
2.6. Harvesting adult brain for histology 
Adult mice were euthanized using Euthasol. Mice were perfused via the cardiovascular 
system with PBS followed by 4% paraformaldehyde (Alfa Aesar, Ward Hill, MA, USA). 
Brains were removed and postfixed in 4% paraformaldehyde overnight at 4oC. Postfixed 
brains were cryopreserved in 30% sucrose for 3 days at 4o C and then embedded in OCT 
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(Tissue-Tek, Torrance, CA, USA). The embedded brains were kept at -80o C until 
sectioning. 
 
2.7. RNA extraction and RT-PCR 
RNA extraction of placenta and fetal brain was based on the manufacturer’s protocol 
(Trizol; Life Technologies, Grand Island, NY, USA). The RNA concentration and quality 
were measured by NanoDrop (Thermo Scientific, Wilmington, DE, USA). Before reverse 
transcription, RNA was treated with DNase I (Promega, San Luis Obispo, CA, USA) to 
eliminate genomic DNA contamination. 1µg RNA from each sample was reverse 
transcribed by using the iScript cDNA synthesis kit (Bio-Rad, Hercules, CA, USA).  
 
2.8. Quantitative PCR (qPCR) 
The gene expression of fetal brain subregions analysis was measured using Power SYBR 
Green PCR master mix (Life Technologies, Carlsbad, CA, USA) on ABI Prism 7900HT 
system (Life Technologies, Carlsbad, CA, USA). All other mRNA expression was 
measured using FastStart Universal SYBR Green master mix with ROX (Roche, El 
Cerrito, CA, USA) on the ABI 7300 real-time PCR system (Life Technologies, Carlsbad, 
CA, USA). Gene expression was normalized to β-actin mRNA. Data are presented as 
fold-change in gene expression in each group relative to that in the maternal saline 
control group. The primer sequences were adapted from the Harvard PrimerBank 
database (Spandidos et al., 2010). 
 
2.9. Luminex cytokine array 
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Fetal brains were dissected at 3 hours post-poly(I:C) injection and homogenized in Tissue 
Extraction Reagent I (Invitrogen, Life Technologies, Carlsbad, CA, USA) containing 
EDTA-free protease inhibitors (Roche, El Cerrito, CA, USA). For cytokine profiling, 
mouse 20-plex cytokine arrays (Invitrogen, Life Technologies, Carlsbad, CA, USA) were 
analyzed on the Luminex FLEXMAP 3D platform by the Clinical Immunobiology 
Correlative Studies Laboratory at the City of Hope (Duarte, CA). These cytokines, 
chemokines growth factors were chosen because of the relevance to the level of IL-6. 
Cytokine levels were normalized to total protein content as detected by BCA assay.  
 
2.10. Cryosectioning 
For fetal brain sectioning, whole embryos were sectioned sagittally at a thickness of 30 
µm and adhered to a Superfrost Plus microscope slide (Fisher Scientific, Tustin, CA, 
USA). For placenta sectioning, placentas were cut sagittally at a thickness of 16 µm. 
Slides were stored at -80o C until staining. For adult brain sectioning, 50 µm sagittal 
sections were cut at -20o C and stored as free-floating in PBS at 4o C until staining.  
 
2.11. Immunohistochemistry  
For colorimetric staining, the sections were postfixed with 4% paraformaldehyde for 10 
min at room temperature. To eliminate endogenous peroxidase activity, the sections were 
incubated with 0.6 % hydrogen peroxide (Sigma, St. Louis, MO, USA) for 30 min at 
room temperature. For pSTAT3 staining, antigen retrieval was conducted after 
endogenous peroxidase elimination. The slides were incubated in 10 mM sodium citrate 
pH 6.0 for 30 min in a 95 °C water bath. After incubation, slides were equilibrated to 
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room temperature. To prevent non-specific binding of antibodies, the sections were 
incubated with blocking solution (10% goat serum, 0.1% triton X-100, and 0.02% sodium 
azide in PBS) for 1 hour at room temperature. After blocking, the sections were incubated 
with primary antibody made in blocking solution overnight at room temperature. On the 
next day, the sections/slides were incubated with biotinylated secondary antibody for 2 
hours at room temperature. Lastly, the sections were incubated in VECTASTAIN ABC 
kit (Vector Laboratories Inc, Burlingame, CA, USA) for 1 hour at room temperature and 
then developed using the VECTOR NovaRED peroxidase substrate kit (Vector 
Laboratories Inc, Burlingame, CA, USA) according to the manufacturer’s instructions. 
Between each step, slides were thoroughly washed with PBS. The sections were 
dehydrated by xylene and then mounted with Permount mounting medium (Fisher 
Scientific, Tustin, CA, USA). 
For fluorescence staining, the sections were postfixed with 4% paraformaldehyde for 10 
min at room temperature. After fixation, the sections/slides were incubated in primary 
antibody made in blocking solution (10% horse serum, 0.1% triton X-100, and 0.02% 
sodium azide in PBS) overnight at room temperature. The next day, sections were 
incubated wtih fluorescence-conjugated secondary antibody for 2 hours at room 
temperature. Between each step, sections were thoroughly washed with PBS. ProLong 
gold, anti-fade mounting medium (Molecular Probe, Life Technologies, Carlsbad, CA, 
USA) was applied to the slide before coverslip mounting.  
Free-floating sections were mounted to Superfrost Plus microscope slides (Fisher 
Scientific, Tustin, CA, USA) after staining. For slide staining, a barrier was drawn on the 
edge of microscope slide by using ImmEdge Hydrophobic Barrier Pen (Vector 
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Laboratories Inc, Burlingame, CA, USA). 
The primary antibodies and their dilutions were rabbit anti-IL-6Rα (1:500; Santa Cruz, 
CA, USA), rabbit anti-Phosphorylation of the transcription factor Signal Transducer and 
Activator of Transcription 3 (pSTAT3; 1:500; Cell Signaling, Danvers, MA, USA), 
mouse anti-NeuN (1:500; Millipore, Darmstadt, Germany), rabbit anti-GFAP (1:500; 
DAKO, Glostrup, Denmark), rabbit anti-calbindin (1:1000; Abcam, Cambridge, MA, 
USA), mouse anti-GAD67 (1:1000; Millipore, Darmstadt, Germany), mouse anti-
parvalbumin (1:1000; Sigma, St. Louis, MO, USA). The fluorescence-conjugated 
secondary antibodies were donkey anti-rabbit (1:1000), and donkey anti-mouse (1:1000) 
(all from Molecular Probes, Life Technologies, Carlsbad, CA, USA). The biotinylated 
secondary antibody was biotinylated goat anti-rabbit IgG antibody (1:200; Vector 
Laboratories Inc, Burlingame, CA, USA). Colorimetric staining images were taken using 
the Nikon DIAPHOT 300 (Nikon, Tokyo, Japan) with SPOT software (V4.6, Sterling 
Heights, MI, USA). Confocal imaging was done using the Zeiss LSM 5 Exciter inverted 
laser scanning microscope (Carl Zeiss MicroImaging Gmbh, Jena, Germany) with Zen 
2009 software (Carl Zeiss MicroImaging Gmbh, Jena, Germany). Quantification of 
pSTAT3, calbinidin, and parvalbumin positive cells was analyzed using ImageJ software 
(NIH, Bethesda, MD, USA).  
For quantification of pSTAT3+ cells in placental spongiotrophoblast, the region of 
interest (ROI) was first selected by a segmented line. All images were converted to 8 bit, 
thresholds were set between 2.71 and 0.37 after calibration. The optical density for the 
ROI was analyzed by measurement of area fraction. The final value of optical density for 
each sample is and average of 5-6 sections. For the quantification of pSTAT3+ cells in 
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fetal brain, positive cells were manually counted by the cell counter from serial sections 
of whole fetal brains. The final number of positive cells is an average of multiple sections. 
For quantification of calbindin+ and parvalbumin+ cells in adult cerebellar lobule VII, 
confocal images for each sample were collected from different focal planes with 2.5 µm 
intervals, converted to Z-stacks and merged into a 2D image by maximum pixel intensity 
using Zen 2009 software. Positively stained cells were quantified using a manual cell 
counter. Cerebellum sections for each mouse were collected every 0.2 mm. The 
coordination for lobule VII quantification was from medial to lateral (ML) -0.04 mm to 
1.20 mm relative to Bregma (bilateral). The length of the Purkinje cell layer was 
measured by a segmented line and further calibrated to the actual length. The final 
number of positive cells reported is averaged from multiple sections. 
 
2.12. X-gal staining 
Brain sections were incubated with rinse buffer (pH 7.3 100 mM sodium phosphate, 2 
mM MgCl2, 0.01% sodium deoxycholate, 0.02% NP-40) 3 times for 40 min at room 
temperature. After rinsing, sections were stained in the rinse solution containing 5 mM 
potassium ferricyanide, 5 mM potassium ferrocyanide, and 1 mg/ml X-gal (from 25 
mg/ml stock in dimethylformamide) for 24 hours. After staining, sections were postfixed 
in 4% paraformaldehyde for 10 min at room temperature. 
 
2.13. Laser capture microdissection (LCM) and transcriptome amplification 
Fetal brains were cut into 16 µm sections on PALM Membrane Slides (415190-9081-
000, MembraneSlide, Carl Zeiss, North York, ON, Canada). Cryostat blades and 
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workstations were cleaned with RNaseZap (Applied Biosystems, Life Technologies, 
Carlsbad, CA, USA) to prevent RNA degradation. 10 sagittal sections were used for 
LCM. Duration was limited to <30 min per slide to prevent RNA degradation. For each 
fetal brain section, the hindbrain was localized by morphology under the Axio 
Observer.Z1 confocal microscope (Zeiss; Thornwood, NY). Conservative regions of 
interest encompassing approximately 100 cell nuclei were microdissected (energy: 50-53; 
focus: 73) using the PALM Microbeam system and PALMRobo software 4.3 (Zeiss; 
Thornwood, NY) and immediately catapulted into an AdhesiveCap 200 microcentrifuge 
tube (415190-9181-000, Carl Zeiss, North York, ON, Canada Zeiss). RNA isolation was 
performed immediately as described above, with the RNeasy Micro Plus kit (Qiagen, 
Gaithersburg, MD, USA). Genomic DNA was removed using gDNA eliminator columns 
(Qiagen, Gaithersburg, MD, USA). Total RNA was amplified and reverse-transcribed 
using the QuantiTect Whole Transcriptome Amplification kit (Qiagen, Gaithersburg, 
MD, USA). 100 ng cDNA was used for qPCR, according to the methods described 
above.  
 
2.14. Behavior 
Experimental procedures 
All mice that underwent behavior testing were maintained under the same conditions as 
described in subsection 2.1. Mice were weaned at the age of 3 weeks. There is no 
significant difference in litter sizes across treatment groups (Saline: 7.3±1.2 offspring, 
MIA: 7.3±2.2 offspring) and sex ratios across treatment groups (Saline Cre-: Male 
1.8±0.8, Female 1.4±1.1; Saline Cre+: Male 2.8±1.5, Female 1.6±1.1; MIA Cre-: Male 
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1.9±2.3, Female 1.9±1.9; MIA Cre+: Male 1±1.7, Female 2.6±2.1). Both male and 
female mice were behaviorally tested (male female ratio is 1:1). The male mice were 
tested prior to female mice in order to avoid the interference of female scent. All behavior 
tests were performed at 13:00-19:00 daily. The experimenter was blinded from the 
genotypes while performing behavioral testing and analyzing behavioral data. 
 
Timeline 
Marble burying was performed at 7 weeks of age. The 3-chamber social test was 
performed at 8 weeks of age. All the apparatuses were cleaned with 70% ethanol and then 
tap water between subjects. Cage bedding was not changed 3 days prior to behavioral 
testing. Mice were acclimated to the testing room at least 30 min before each behavior 
test.  
 
3 chamber social test 
The design and procedure for the 3 chamber social test was modified from previous 
literature (Yang et al., 2011). The social chamber is a 40 (width) x 20 (length) x 22 
(height) cm Plexiglas box divided equally into 3 chambers by transparent walls made by 
Plexiglas with the opening doors (10 cm width x 5 cm height). The procedure consisted 
of two consecutive phases- habituation and sociability. In habituation phase, mouse was 
placed in the center of the social chamber for 10 min and allowed to freely explore each 
compartment. In the sociability phase, the testing mouse was enclosed in the center 
compartment of social chamber with the doors closed. Two inverted steel wire cups were 
placed in each of the two side chambers. An unfamiliar, strain-, age- and gender- 
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matched mouse was placed in one of the inverted wire cups. The unfamiliar mice were 
purchased from Jackson Laboratory (Bar Harbor, ME, USA). The other inverted wire cup 
represented a novel object. After setting up, the doors were opened, and the mouse was 
allowed to investigate the chamber for 10 min. The behavior was recorded by a video 
camera mounted above the apparatus. Ethovision (Noldus Information Technology, 
Leesburg, VA, USA) was used to analyze the duration of the mouse in each chamber. 
Mice were only excluded from the data if they showed biased preference to a certain side 
of chamber during habituation phase. 
 
Marble burying test 
Marble burying is a test for repetitive behavior. The procedure has been previously 
described (Malkova et al., 2012) with modification. The mouse was first acclimated to a 
test cage with compressed, 5-cm deep clean, Aspen pine bedding. After this habituation 
the mouse was returned to its home cage. 20 navy blue glass marbles (15 mm diameter) 
were gently placed on the bedding of the test cage (4 x 5 arrangement). The mouse was 
then returned to this test cage and, after 10 min, the number of buried marbles was 
counted. The criteria for a buried marble was over 50% of the marble covered by 
bedding. The marbles were cleaned with 70% alcohol, dried, and submerged in Aspen 
pine bedding between each test. 
 
2.15. Statistic analysis  
All data are represented as mean ± standard error mean (SEM). The fetus/offspring used 
for qRT-PCR, cytokine array, immunohistochemistry were collected from at least 3 
independent litters per group. The offspring used for behavior testing were pooled from at 
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least from 6 independent litters per group. The data were analyzed by using a litter as an 
n number in order to minimize potential confounding litter effect. All offspring were used 
for each litter. Specifically, the readouts of the offspring from each litter were averaged 
and used the averaged number to be the biological replicate (Wu et al., 2015). Analysis 
with the two-tailed unpaired t test was used to compare data between two groups. Data 
with two variable factors were analyzed by two-way ANOVA with post-hoc test. The 
data analyzed using Prism 6.0 (Graphpad, La Jolla, CA, USA) and with SigmaStat 3.5 
(Systat, San Jose, CA, USA). p value is used to justify the significance between groups. 
When p is smaller than 0.05, the groups are considered as different. The number of 
asterisks indicates the difference in the Figures.  
 
3. RESULTS 
3.1. Increased IL-6 expression levels in MIA fetal brain 
To determine the temporal pro-inflammatory responses of MIA on the developing 
offspring, we analyzed fetal brain Il6 gene expression at different time point after 
injection of poly(I:C) to dams at embryonic day 12.5 (E12.5). Brain Il6 levels are higher 
in fetuses from poly(I:C)-treated dams compared to saline treated dams at 3 hours post-
injection (Fig. 1A). Il6 levels return to baseline at 6 and 24 hours post-poly(I:C) injection 
(Fig. 1A). Thus, the rapid and transient elevation of Il6 gene expression in fetal brain 
represents an acute inflammatory insult to the developing fetus. 
 
3.2. The transcription factor STAT3 and downstream signaling are activated in the 
hindbrain of the MIA fetus 
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 pSTAT3 is a downstream activation marker of cytokine signaling. 
Immunohistochemistry analysis of pSTAT3 in the brain of embryos at 3 hours post- 
poly(I:C) injection revealed spatially restricted immune activation following MIA. 
Several central and peripheral areas in the fetus display positive pSTAT3 staining, 
including the hindbrain, trigeminal ganglion (Fig. 1B, Supplementary Fig. S1-S3). The 
most dramatic changes in pSTAT3 levels are in hindbrain areas—specifically the 
prepontine hindbrain (PPH) and pontine hindbrain (PH) (Fig. 1B, low magnification in 
Supplementary Fig. S1A and detailed annotation in Fig. S1B). These two hindbrain 
areas develop into the cerebellum and brainstem (Puelles et al., 2013), sites of 
dysfunction in some cases of autism (Courchesne, 1997; Rodier et al., 1996; Wang et al., 
2014). The distribution of pSTAT3+ cells is significantly higher in the MIA fetal brain 
compared to saline controls within the PPH and PH (Fig. 1C), and largely localize to the 
lateral side of the fetal brain.  
To further analyze regional-specific pro-inflammatory responses identified by pSTAT3 
staining, we collected the PH by LCM (Supplementary Fig. S1C), and examined the 
expression of genes relevant to the JAK/STAT3 signaling pathway. Following MIA 
induction, Stat3 and Myc expressions are significantly increased in the PH (Fig. 1D). This 
is consistent with the finding that Myc is a central “hub” in signaling pathways enriched 
in the ASD brain (Ziats and Rennert, 2011). Taken together, these data reveal that MIA 
induces increased cytokines expression and activation of STAT3 signaling pathways 
within specific brain regions in the developing fetus. 
 
3.3. Maternal IL-6 is required for immune activation in the fetal brain during MIA 
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Based on the finding that IL-6 is induced directly in the fetal brain following MIA, in 
addition to previous reports revealing that MIA elevates IL-6 in the maternal blood and 
placenta, we aimed to determine whether maternal IL-6 is required for the priming of 
acute inflammatory response in the fetal brain. Wild-type male mice were crossed to Il6-/- 
females and, in parallel, Il6-/- males were crossed to wild-type females. MIA was induced 
in pregnant females, generating Il6+/- MIA offspring in both cases. IL-6, IL-4, and IP-10 
protein levels are increased in the Il6+/- fetal brain of offspring from wild-type females 
that have been injected with poly(I:C), compared to saline controls (Fig. 1E). 
Furthermore, elevation of IL-6, IL-4, and IP10 in the Il6+/- fetal brain were not observed 
upon injection of poly(I:C) into Il6-/- females, indicating that maternal sources of IL-6 are 
required for acute induction of cytokines in the fetal brain after MIA. In addition, 
maternal IL-6 is required for maintaining baseline levels of FGF-basic, IL-2, IL-
12p40/p70, KC, and VEGF. These data demonstrate that IL-6 protein expression in the 
mother exacerbates an inflammatory program in the fetus that may impact brain function 
and development. Though this finding does not rule out a role for IL-6 signaling outside 
the fetal brain, it prompted us to examine how IL-6 at the maternal-fetal interface 
transmits immune activation and behavioral deficits to the fetus. 
 
3.4. Generation of placental trophoblast Il6ra conditional knockout mice 
To validate Cyp19-Cre recombinase-mediated Il6ra deletion, we analyzed mRNA and 
protein levels for the IL-6Rα in the placenta. Analysis of whole placenta RNA extracts 
from the Cyp19-Cre+;Il6rafl/fl group shows a ~50% reduction in the Il6ra transcript level 
compared to the Il6rafl/fl group, regardless of MIA induction, which indicates that Cyp19-
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Cre is specifically localized at SP layer, instead of whole placenta (Fig. 2A). Antibody 
staining of placental tissue sections for IL-6Rα shows minimal expression in the SP layer 
of Cyp19-Cre+;Il6rafl/fl mice. In contrast, a few IL-6Rα+ cells can be detected in SP layer 
of the saline control and placenta from MIA-treated Il6rafl/fl offspring (Supplementary 
Fig. S4). In addition, knockout of Il6ra does not alter Il6 gene expression in the placenta, 
as elevation of Il6 is detected in MIA mice regardless of receptor expression (Fig. 2B). 
To confirm that Cyp19-Cre is not residually expressed directly in the brain, we evaluated 
β-galactosidase expression in the brains of Cyp19-Cre+;ROSA::LSL-lacZ mice. β-
galactosidase staining is absent in the brains of Cyp19-Cre+;ROSA::LSL-lacZ mice, while 
the positive control shows strong expression across different brain regions 
(Supplementary Fig. S5). Moreover, IL-6Rα is intact in the calbindin+ cerebellar 
Purkinje cells and brainstem motor trigeminal nucleus (MO5) of Cyp19-Cre+;Il6rafl/fl 
brains (Supplementary Fig. S6). No difference is observed in the global distribution of 
neurons and astrocytes across various adult brain regions in Cyp19-Cre+;Il6rafl/fl 
offspring compared to Il6rafl/fl offspring (Supplementary Fig. S7). Further, there are no 
differences in body weights between Cyp19-Cre+;Il6rafl/fl and Il6rafl/fl offspring 
(Supplementary Fig. S8).  
 
3.5. Knockout of placental trophoblast Il6ra blocks MIA induced pSTAT3 activation in 
spongiotrophoblast layer and placental Prl2b1 gene expression 
pSTAT3 is increased in the placenta 3 hours post-poly(I:C) injection, with a maternal IL-
6 dependent activation of pSTAT3 in the SP layer (Hsiao and Patterson, 2011). We 
observed the same effect in MIA-induced Il6rafl/fl mice, as the distribution of pSTAT3+ 
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cells dramatically increase in the SP layer of MIA Il6rafl/fl placentas compared to saline 
controls, while this increase is not observed in Cyp19-Cre+;Il6rafl/fl mice (Fig. 2C and 
2E). Furthermore, knockout of Il6ra in the placental trophoblasts blocks pSTAT3 
activation in the SP layer of the placenta following MIA treatment, but not in saline 
controls (Fig. 2C and 2E). To corroborate the observation that IL-6 signaling is inhibited 
in the placenta of these mice, levels of Prl2b1 (Prolactin family 2 subfamily b member 1 
hormone) were also examined. Prl2b1 is a placenta specific protein expressed in multiple 
trophoblast lineages (Dai et al., 2000), and we previously demonstrated that Prl2b1 
expression is elevated in the placenta of poly(I:C)-treated dams, in a maternal IL-6-
dependent manner (Hsiao and Patterson, 2011). An interaction of Cre and MIA is 
detected in Prl2b1 expression (Fig. 2D). Il6rafl/fl and Cyp19-Cre+;Il6rafl/fl do not differ in 
placental Prl2b1 expression in saline treated groups; however, for the MIA treatment, 
Prl2b1 expression is significantly lowered in Cyp19-Cre+;Il6rafl/fl compared to Il6rafl/fl 
placenta. In addition, in the Il6rafl/fl placenta, Prl2b1 expression is increased in the MIA 
treated group. Within the Cyp19-Cre+;Il6rafl/fl placenta, there is no difference between 
saline and MIA groups. Overall, these experiments confirm that knockout of IL-6Rα in 
the placenta abolishes IL-6-dependent responses in placental pSTAT3 activation and 
downstream gene expression.  
 
3.6. Inhibition of placental IL-6 signaling prevents immune responses in the fetal brain 
To determine whether placental IL-6 signaling after MIA is required for the elevated Il6 
gene expression observed in fetal brain, we analyzed the pro-inflammatory response in 
fetal brains of Cyp19-Cre+;Il6rafl/fl mice. Gene expression analysis shows that Il6 gene 
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expression is increased in Il6rafl/fl fetal brains after MIA induction, but not in Cyp19-
Cre+;Il6rafl/fl fetal brains (Fig. 3A). pSTAT3 activation in the fetal brain is also reduced 
following inhibition of IL-6 signaling in the placenta (Fig. 3B-3E). Specifically, within 
the fetal PPH, a main effect for Cre and an interaction for Cre and MIA are detected in 
fetal brain pSTAT3 activation. Knockout of trophoblast Il6ra results in the reduction of 
pSTAT3+ cells in the fetal PPH following MIA induction. However, the distribution of 
pSTAT3+ cells in the fetal PPH is not different between Il6rafl/fl and Cyp19-Cre+;Il6rafl/fl 
fetuses in saline controls (Fig. 3B and 3D). In addition, for Il6rafl/fl fetal brains, MIA 
increases the distribution of pSTAT3+ cells in the PPH; however, in Cyp19-Cre+;Il6rafl/fl 
fetal brains, numbers of pSTAT3+ cells for saline and MIA are similar. Within the fetal 
PH, knockout of trophoblast Il6ra results in the reduction of pSTAT3+ cells in both saline 
and MIA groups (Fig. 3C and 3E). There is no difference in pSTAT3+ cells in the PH 
between saline and MIA in both Il6rafl/fl and Cyp19-Cre+;Il6rafl/fl fetal brains. These data 
reveal that MIA-induced IL-6 signaling at the maternal-fetal interface of the placenta 
leads to activation of the immune system within the fetal brain. 
 
3.7. Knockout of placental Il6ra prevents cerebellum neuropathology in MIA offspring  
Loss of Purkinje cells in lobule VII of the cerebellum is one of the neuropathological 
phenotypes seen in the MIA model as well as in ASD (Naviaux et al., 2013; Shi et al., 
2009; Skefos et al., 2014). To determine whether inhibition of placental trophoblast IL-6 
signaling can prevent the loss of Purkinje cell in adulthood, we visualized calbindin+ 
Purkinje cells in adult brain sections from control and trophoblast IL-6Rα deficient 
offspring born to immune-activated mothers. A reduction in calbindin+ Purkinje cells was 
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observed in the cerebellar lobule VII of Il6rafl/fl offspring following MIA compared to 
saline Il6rafl/fl controls (Fig. 4A and 4A’). The reduction of calbindin+ Purkinje cells in 
the cerebellar lobule VII by MIA is not observed in Cyp19-Cre+;Il6rafl/fl offspring (Fig. 
4A’’’ and B). Due to an interaction of Cre and MIA, we further analyzed calbindin+ 
Purkinje cells between Il6rafl/fl and Cyp19-Cre+;Il6rafl/fl offspring. Remarkably, for the 
MIA group, Cyp19-Cre+;Il6rafl/fl offspring display significantly greater densities of 
calbindin+ Purkinje cells in the cerebellar lobule VII compared to Il6rafl/fl offspring (Fig. 
4A’ and 4A’’’). However, in saline control animals, calbindin+ Purkinje cells do not 
differ between Il6rafl/fl and Cyp19-Cre+;Il6rafl/fl offspring (Fig. 4A and 4A”). These 
results suggest that elevated placental IL-6 signaling in response to MIA is required to 
perturb the neurodevelopment of Purkinje cells in lobule VII. 
Dysfunction of inhibitory neurotransmission has been described in ASD patients and 
mouse models (Coghlan et al., 2012). To understand whether the inhibitory neurons of 
Purkinje cell populations are affected by MIA, we co-stained calbindin with the 
inhibitory neuronal markers – parvalbumin and glutamate decarboxylase 67 (GAD67). 
Co-staining indicates that Purkinje cells that express calbindin also express parvalbumin 
and GAD67 in lobule VII (Fig. 4A and Supplementary Fig. S9). Offspring whose 
mothers were treated with MIA not only contain fewer calbindin+ cells, but also display 
lower proportions of parvalbumin+ cells in the Purkinje cell layer (PCL) of lobule VII. 
This reduction is more pronounced in Il6rafl/fl offspring (Fig. 4A and 4C). In addition, 
although an interaction of Cre and MIA is detected, there is no detectable difference 
between Il6rafl/fl and Cyp19-Cre+;Il6rafl/fl offspring in both saline and MIA groups (Fig. 
4A and 4C). The reduction of parvalbumin+ cells by MIA is restricted to the PCL, 
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whereas parvalbumin+ cells are intact in molecular layer (ML) of the cerebellum (Fig. 
4A). There is no detectable difference in GAD67 staining in the PCL between offspring 
of saline and MIA Il6rafl/fl mice (Supplementary Fig. S9). Collectively, these data show 
that activation of the IL-6 pathway in the placenta leads to MIA-induced Purkinje cell 
defects in offspring, a neuropathology also found in ASD. 
 
3.8. Knockout of placental Il6ra prevents behavioral abnormalities in the MIA model  
MIA offspring exhibit behavioral abnormalities relevant to ASD (Hsiao et al., 2013). 
Here, we reveal that placental IL-6 signaling during gestation is a key mediator of MIA-
induced impairments in social and marble burying behaviors (Fig. 5A-C). In the 3-
chamber social test, the time spent in mouse chamber (social) and object chamber 
(asocial) is not different in MIA Il6rafl/fl mice (Fig. 5A), whereas offspring in other group 
spend more time in the mouse chamber compared to the object chamber (Fig. 5A). 
Similarly, when we further analyzed the investigation time toward stranger mouse and 
object, MIA Il6rafl/fl offspring have no preference in investigating a stranger mouse and 
an object (Fig. 5B), whereas other groups investigate the stranger mouse more than 
object (Fig. 5B). Thus, placental IL-6 signaling impacts social interaction in offspring. 
Finally, in the marble burying paradigm for repetitive/stereotyped behavior, an 
interaction of Cre and MIA is detected in marble burying behavior. Following MIA 
treatment, knockout of placental Il6ra results in the reduction of offspring marble burying 
behavior when compared to Il6rafl/fl offspring. However, for the saline treatment groups, 
marble burying behavior does not differ between Cyp19-Cre+;Il6rafl/fl and Il6rafl/fl 
offspring (Fig. 5C). Furthermore, MIA results in the increase of marble burying behavior 
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in Il6rafl/fl offspring, whereas MIA has no effect on marble burying behavior in Cyp19-
Cre+;Il6rafl/fl offspring (Fig. 5C). In addition, no sexual dimorphism in MIA-related 
behavioral abnormalities was observed in Cyp19-Cre+;Il6rafl/fl offspring 
(Supplementary Fig. S10). These results indicate that placental IL-6 signaling is 
required for MIA-induced behavioral abnormalities in social and marble burying 
behaviors. 
 
4. DISCUSSION 
The ASD risk factor, MIA, initiates an immunologic program that leads to offspring with 
abnormalities in fetal brain development and behavioral deficits. Our study demonstrates 
that placental IL-6 signaling, specifically in the trophoblast, is required for MIA-induced 
acute immune activation in the fetal brain, as well as downstream neuropathologies and 
behavioral impairments. These findings contribute to the increasing appreciation that 
interactions at the maternal-placental-fetal interface play an important role in relaying the 
effects of maternal gestational insults to the developing embryo.  
However, the events linking transiently elevated fetal brain cytokines to neuropathologies 
and behavioral deficits remain to be defined. Previous studies of the MIA model reveal 
that although MIA itself is transient, it results in dynamic and long-lasting changes to 
cytokine profiles across gross regions of the early postnatal and adult brain (Garay et al., 
2013). In addition, MIA in mothers leads to durable programming of persistent immune 
dysregulation in adult offspring (Hsiao et al., 2012). Epigenetic alterations have been 
reported in MIA, and may mediate the long-term effects of transient immune activation 
(Connor et al., 2012). Therefore, transient induction of IL-6 in the fetal brain, during 
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critical period of neurodevelopment, appear to set in motion events that lead to adverse 
neuropathological and behavioral outcomes in adulthood.  
Herein, we demonstrate that initiating the MIA cascade through placental IL-6 signaling 
leads to adverse effects in the offspring. Three different pathways may contribute to the 
link between placental IL-6 expression and downstream responses in the fetal brain. First, 
the placenta may initiate a feed-forward cycle of IL-6 induction in the embryo. Maternal 
IL-6 can directly cross the placenta and reach the fetus during mid-gestation, but not late 
gestation in rats, which aligns well with the finding that the placenta exhibits higher 
permeability during mid-gestation compared to late gestation (Dahlgren et al., 2006). 
Interestingly, expression of suppressor of cytokine signaling 3 (SOCS3), a key factor 
involved in the negative inhibition of IL-6 activity, is absent in the SP layer of placenta 
between E7-E14, while both STAT3 and pSTAT3 are present (San Martin et al., 2013), 
which may support the notion that IL-6 triggers a feed-forward cycle of cytokine 
signaling to propagate the MIA inflammatory signal in the absence of its native 
suppressor. 
A second potential mechanism underlying the link between placental IL-6 signaling and 
fetal brain status is modulation of placental hormones. Hormone imbalance could 
profoundly impact placental and embryonic development. We find herein that placental 
Prl2b1 gene expression is upregulated after MIA, but absent in placenta lacking 
trophoblast-specific IL-6 signaling. Prl2b1 is speculated to play a role in the regulation of 
placental angiogenesis and uterine growth (Dai et al., 2000). Further, placental 
corticotrophin-releasing factor (CRF) signaling is another pathway that may affect MIA 
response. Placenta derived CRF secretion has been shown in response to different 
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conditions during pregnancy, including infectious stress (Florio et al., 2002). In vitro 
studies reveal that CRF can inhibit IL-6 production induced by endotoxin in human 
mononuclear cells (Hagan et al., 1992), which suggest other possible mechanisms for 
CRF activity in contributing to MIA dependent outcomes. Future studies warrant 
examination of additional placental hormones and functional evaluation of how changes 
in their expression impact embryonic development.  
A third pathway by which placental IL-6Rα signaling may lead to altered 
neurodevelopment involves an effect of MIA directly on placental permeability. In the 
placenta, tight junction proteins provide a barrier between the mother and fetus in 
regulating the exchange of materials, and the permeability of the placenta can be altered 
during inflammation. Chorioamnionitis-induced upregulation of proinflammatory 
cytokines decreases expression of tight junction proteins in trophoblastic and endothelial 
cells of the placenta, facilitating infection (Tossetta et al., 2014). Furthermore, co-culture 
of human umbilical vein endothelial cells with the placental trophoblast cells from 
women with preeclampsia results in decreased barrier function of endothelial cells. The 
endothelial tight junctions become more vulnerable, which indicates that placenta 
trophoblast-derived factors are able to change the vascular permeability in the placenta 
(Wang et al., 2004). How such changes in the placenta alter the metabolic and nutrient 
milieu in the developing embryo is unclear. However, we recently discovered that MIA 
offspring display increased gut permeability, which allows potentially neurotoxic 
molecules to leak into the circulation and impact behavior (Hsiao et al., 2013). Tracking 
metabolites from mother to fetus following placental IL-6 signaling may reveal insights 
into biological links between placental status and neurodevelopment.  
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Notably, the role of soluble IL-6Rα (sIL-6Rα) in the MIA model is still not clear. In 
mouse, 93.4% of circulating sIL-6Rα is contributed by granulocytes, macrophages, and 
hepatocytes as demonstrated by a conditional IL-6Rα knockout approach (McFarland-
Mancini et al., 2010). Cyp19-Cre is expressed in trophoblast precursor cells and 
predominately distributed within the spongiotrophoblasts, labyrinth trophoblasts, and 
giant cells of the placenta (Wenzel and Leone, 2007). While the Cyp19-Cre+;Il6rafl/fl 
mice used in this study exhibited intended deficiencies in placental IL-6R gene 
expression, whether signaling through sIL-6Rα occurs on IL-6R-deficient trophoblasts is 
unclear. sIL-6Rα is thought to be derived by either proteolytic cleavage of the membrane 
moiety to liberate the extracellular portion of the receptor or by alternative splicing of the 
IL-6R transcript. It is possible that sIL-6Rα derived from non-trophoblastic sources in the 
placenta or from the maternal bloodstream could bind to gp130 on IL-6R-deficient 
trophoblasts; however, our data showing that MIA-associated STAT3 activation is 
abrogated in trophoblast cells from Cyp19-Cre+;Il6rafl/fl mice suggests that signaling 
through any available sIL-6Rα is not a major confounding factor. Additional studies are 
warranted to examine the role of sIL-6Rα in the MIA model. 
Although we observe that blocking IL-6 signaling in MIA placenta successfully prevents 
detrimental effects to the offspring, whether direct infiltration of inflammatory cells into 
the placenta is involved in this MIA response remains unclear. We previously 
demonstrated MIA increased CD69 expression in decidual natural killer cells (uterine NK, 
uNK), macrophages and granulocytes (Hsiao and Patterson, 2011). The elevation of 
CD69 expression in leukocyte populations was unchanged when induced MIA in IL-6 
deficient dam, indicating that placental inflammatory cell activation is independent of IL-
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6 action (Hsiao and Patterson, 2011). In preliminary studies, we observed no overt 
infiltration of uNK cells or myeloid cells from the decidua or maternal blood spaces into 
the placenta at 3, 6 or 24 hours post MIA induction, but whether other subtypes of 
immune cells or other time points may be affected requires further study.  
Our study demonstrates that blocking IL-6 signaling in the placenta prevents the 
development of a robust neuropathology in ASD, a spatially-restricted deficit in Purkinje 
cells in lobule VII of the cerebellum. Cerebellar injury at birth is a strong risk factor for 
ASD (Wang et al., 2014). Postmortem studies reveal Purkinje cell abnormalities in ASD 
patients (Skefos et al., 2014; Whitney et al., 2008). Most pSTAT3+ cells in the fetal brain 
of MIA offspring are located at cerebellum primordium of PPH. The cerebellum arises 
from the PPH, specifically rhombomere 1 at E9 of gestation, and develops into the wing-
like cerebellar primordium by E12.5 in mice. Purkinje cells arise around E10–E13 
(Hashimoto and Mikoshiba, 2003; Miale and Sidman, 1961). Postmitotic Purkinje cells 
undergo a migration process at E12.5-E15 and start to express calbindin at E14 (Sillitoe 
and Joyner, 2007; Wang and Zoghbi, 2001). MIA is induced during this critical window 
of Purkinje cell development at E12.5. In addition, the other region with elevated 
pSTAT3 is located at the trigeminal ganglion afferents area of PH. It has been 
demonstrated that by altering hindbrain transcription factors during embryonic stage, the 
nerve ascending from the trigeminal ganglion ectopically projects into the cerebellum 
instead of hindbrain (Oury et al., 2006). Based on these finding, hypothetically, induction 
of MIA in the fetus at E12.5 might directly disrupt cerebellum development, Purkinje 
cells generation and hindbrain neural circuitry formation. Blocking IL-6 signaling in the 
placenta during the acute phase of infection is capable of reducing STAT3 activation in 
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the cerebellar primordium of the fetus, and also prevents the deficiency in Purkinje cells 
seen in the cerebellum of MIA offspring.  
We hypothesize that the loss of Purkinje cells in lobule VII of the cerebellum in MIA 
adult offspring is due to an alterations in developmental trajectory. Previous studies 
revealed that deficiencies in lobule VII Purkinje cells could be observed as early as 
postnatal day 11 in offspring of mothers infected with influenza. Moreover, abnormal 
migration of Purkinje cells was also observed at this stage, with ectopic placement of 
some Purkinje cells within the cerebellar lobules (Shi et al., 2009). Based on these 
findings, we speculate that the loss of Purkinje cells observed in adult MIA offspring may 
result from a common mechanism as seen in the infection model, where the generalized 
maternal inflammatory response causes the loss of Purkinje cells in lobule VII in 
offspring during early development. 
Traditionally, the cerebellum is regarded as the brain region responsible for controlling 
motor-related tasks. More recent evidence suggests that the cerebellum may be an 
essential component in processing external sensory inputs to govern movement and 
higher cognitive function (Wang et al., 2014). The association between ASD-like 
behaviors and the loss of cerebellar Purkinje cells has been reported in several mouse 
models with features of ASD-like behavior (Fujita et al., 2012; Reith et al., 2013; Tsai et 
al., 2012). Functional MRI studies demonstrate the connectivity of cerebellum lobule VII 
and the pre-prefrontal and posterior-parietal cortices, which implies lobule VII might be 
involved in higher cognitive function (Habas et al., 2009; O'Reilly et al., 2010). 
Disruption of cerebellar lobule VII development at the embryonic stage may produce 
  
 32
cognitive impairment in offspring, which again points to the importance of intervention 
of immune activation in the maternal environment during the acute phase of infection. 
The role of trigeminal afferent neurons and associated brain nuclei is relatively not well 
understood in ASD. Whether MIA disrupts hindbrain pattern formation and development 
of trigeminal system via activation of inflammatory signaling in the PH, a brain region 
that receives inputs from the trigeminal ganglion, will need further investigation. Prenatal 
exposure of valproic acid (VPA) is another model of an environmental risk factor for 
autism. Intriguingly, injection of VPA between E11.5 and 12.5 leads to reduction of 
motor neuron number in the trigeminal motor nucleus in rat pups (Rodier et al., 1996). 
Furthermore, VPA injection decreases immunoreactivity of neurofilaments in the 
trigeminal nerves of the embryo (Tashiro et al., 2011). Collectively, these studies suggest 
a possible mechanism by which MIA and other maternal insults could perturb 
development of trigeminal innervations.  
As IL-6 is a proinflammatory cytokine in response to bacterial and viral infections, the 
prophylactic effect of blocking IL-6 signaling in placenta could widely applicable across 
different modes of maternal infection. We hypothesize that this preventive effect is not 
only limited to maternal toll-like receptor 3 (TLR3) activation, as we demonstrate by 
using poly(I:C), but can also be effective for other types of maternal immune activation, 
e.g. prenatal activation of TLR4 by administration of the bacterial endotoxin 
lipopolysaccharide (LPS). Prenatal challenge with LPS similarly increases placental IL-6 
during the acute phase of infection in both in vivo and in vitro models (Anton et al., 2012; 
Bell et al., 2004; Bloise et al., 2013; Jin et al., 2015; Urakubo et al., 2001). Furthermore, 
histopathology approaches indicate that prenatal administration of LPS causes 
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mesenchymal hyperplasia, infiltration of neutrophils in the placental labyrinth and 
increase of fibrin deposition at both the spongiotrophoblast and labyrinth zone (Jin et al., 
2015). Moreover, maternal LPS challenge has also been shown to activate pSTAT3 in the 
fetal brain. This pSTAT3 activation in the fetal brain can be neutralized by IL-6 antibody 
(Mouihate and Mehdawi, 2016), indicating IL-6/STAT3 signaling is the key pathway for 
prenatal LPS administration. These results lead to a converging mechanism by which 
maternal infection impacts placental and fetal development via placental IL-6 signaling. 
Our findings support a causal role for placental IL-6/IL-6Rα/STAT3 in MIA models. 
In conclusion, our study reveals that MIA induces an IL-6 surge in the maternal-
placental-fetal axis, resulting in acute fetal brain responses and long-term changes in 
brain development and behavior. We identify signaling of placentally-derived IL-6 
through IL-6Rα on placenta trophoblasts as a key step for relaying the MIA response 
from mother to fetus. Blocking IL-6 signaling in the placenta by trophoblast-specific 
deletion of IL-6Rα effectively prevents downstream immune responses in the fetal brain 
and precludes the development of Purkinje cell deficits and ASD-related behaviors in 
adult offspring. These data contribute to the increasing appreciation for the important role 
of maternal-fetal interactions at the placenta in guiding embryonic neurodevelopment. 
Moreover, our findings suggest that blocking placental IL-6 signaling during the acute 
phase of infection can serve as a preventative therapeutic for the development of 
neuropathological and behavioral symptoms of ASD in At-risk populations. 
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FIGURE LEGENDS 
Fig. 1. MIA induces an acute immune response in the fetal brain. (A) The level of IL-6 in 
fetal brain was measured by qPCR. Fetal brains from poly(I:C)-injected dam exhibit 
elevated Il6 gene expression at 3 hours post-injection (t10 = 2.732, p = 0.0211; Student’s 
two-tailed unpaired t test). No difference in Il6 gene expression is observed between 
saline and MIA fetal brains at 6 and 24 hours post-injection. (3 hr: Saline n = 6 litters (16 
embryos); MIA n = 6 litters (18 embryos); 6 hr and 24 hr: Saline n = 3 litters (9 
embryos); MIA n = 3 litters (9 embryos). Il6 gene expression was normalized to β-actin.  
Gene expression was normalized to β-actin. (B) pSTAT3 is increased in MIA fetal 
hindbrain at 3 hours post-poly(I:C) injection. Representative images of pSTAT3 staining 
in sagittal sections of the MIA fetal prepontine hindbrain (PPH) and pontine hindbrain 
(PH). Scale bar = 200 µm. (C) Quantification of pSTAT3+ cells in the fetal PPH (t7 = 
3.038, p = 0.0189) and PH (t6 = 3.888, p = 0.0081) (Student’s two-tailed unpaired t test). 
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Saline n = 4 litters (7 embryos); MIA n = 5 litters (5 embryos). (D) Downstream 
signaling molecules of the IL-6 pathway in fetal MIA and control LCM samples are 
analyzed by qPCR. The results are normalized to β-actin using the ddCT method. Stat3 
(t4 = 9.483, p = 0.0007) and Myc (t4 = 2.810, p = 0.0483) expression are significantly 
increased in the PH area after MIA (Student’s two-tailed unpaired t test). Saline n = 3 
litters (7-9 embryos); MIA n = 3 litters (9-10 embryos). (E) Luminex cytokine array 
indicates that MIA-mediated alterations in fetal brain cytokines and chemokines depend 
on maternal IL-6 genotype. Values were normalized to white bar. Data shows that 
maternal poly(I:C) injection induces cytokine levels in fetal brain  and that maternal IL-6 
is required for induction of fetal brain IL-4 (Saline WT dam v.s. MIA WT dam p = 
0.0176; MIA WT dam v.s. MIA KO dam p = 0.0238), IL-6 (Saline WT dam v.s. MIA 
WT dam p = 0.0397; MIA WT dam v.s. MIA KO dam p = 0.0465), IP-10 (Saline WT 
dam v.s. MIA WT dam p = 0.0201; MIA WT dam v.s. MIA KO dam p = 0.0012) and for 
maintaining baseline levels of FGF-basic (Saline WT dam v.s. MIA KO dam p < 0.0001; 
MIA WT dam v.s. MIA KO dam p < 0.0001), IL-2 (Saline WT dam v.s. MIA KO dam p 
< 0.0001; MIA WT dam v.s. MIA KO dam p < 0.0001), KC (Saline WT dam v.s. MIA 
KO dam p = 0.0002; MIA WT dam v.s. MIA KO dam p = 0.0012), VEGF (Saline WT 
dam v.s. MIA KO dam p = 0.0004; MIA WT dam v.s. MIA KO dam p < 0.0001) (One-
way ANOVA with Fisher’s LSD post-hoc test). All groups n = 4 litters (4 embryos per 
group). Cytokine levels were normalized to total protein content. * p < 0.05, ** p < 0.01, 
*** p < 0.001, **** p < 0.0001 v.s. saline control. Data are presented as mean ± SEM. 
n.s.: not significant. 
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Fig. 2.  Deletion of placental trophoblast Il6rafl/fl decreases STAT3 activation, but not IL-
6 production after MIA. (A) The level of IL-6Rα in placenta was measured by qPCR. 
Il6ra expression is decreased in the Cyp19-Cre+;Il6rafl/fl placenta. There is no effect of 
MIA on placental Il6ra expression. All groups n = 3 litters (6, 9, 4, 8 placentas were used 
for Saline Cre-; MIA Cre-; Saline Cre+; MIA Cre+, respectively) (MIA: F(1,8) = 0.08604, 
p = 0.8774; Cre: F(1,8) = 72.66, p = 0.0017; MIAxCre: F(1,8) = 0.1413, p = 0.8433; Post 
hoc- Cre- v.s. Cre+: Saline p = 0.0140, MIA p = 0.0091) (Two-way ANOVA with 
Fisher’s LSD post-hoc test). (B) The level of IL-6 in placenta was measured by qPCR. 
MIA increases Il6 gene expression in both Il6rafl/fl and Cyp19-Cre+;Il6rafl/fl placentas. 
There is no effect of Il6ra genotype on placental Il6 gene expression in response to MIA. 
Il6 gene expression was normalized to β-actin. All groups n = 3 litters (6, 9, 4, 8 
placentas were used for Saline Cre-; MIA Cre-; Saline Cre+; MIA Cre+, respectively) 
(MIA: F(1,8) = 78.65, p = 0.0006; Cre: F(1,8) = 0.4826, p = 0.6780; MIAxCre: F(1,8) = 
0.06658, p = 0.8768; Post hoc- Saline v.s. MIA: Cre- p = 0.0054, Cre+ p = 0.0039) (Two-
way ANOVA with Fisher’s LSD post-hoc test). (C) Quantification of pSTAT3 optical 
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density in the placental spongiotrophoblast (SP) layer. All groups n = 3 litters (3 
placentas per group). (MIA: F(1,8) = 25.34, p = 0.001; Cre: F(1,8) = 8.906, p = 0.0175; 
MIAxCre: F(1,8) = 4.794, p = 0.06; Post hoc- Saline v.s. MIA: Cre- p = 0.0009, Cre+ p = 
0.0791; Cre- v.s. Cre+: Saline p = 0.5895, MIA p = 0.0064) (Two-way ANOVA with 
Fisher’s LSD post-hoc test) (D) The level of Prolactin family 2 subfamily b member 1 
hormone in placenta was measured by qPCR. MIA increases Prl2b1 expression in the 
Il6rafl/fl placenta. This elevation is prevented in placentas from MIA Cyp19-Cre+;Il6rafl/fl 
mice. All groups n = 3 litters (5, 6, 5, 6 placentas were used for Saline Cre-; MIA Cre-; 
Saline Cre+; MIA Cre+, respectively) (MIA: F(1,8) = 3.657, p = 0.0922; Cre: F(1,8) = 5.159, 
p = 0.0528; MIAxCre: F(1,8) = 16.58, p = 0.0036; Post hoc- Saline v.s. MIA: Cre- p = 
0.0029, Cre+ p = 0.1653; Cre- v.s. Cre+: Saline p = 0.2388, MIA p = 0.0020) (Two-way 
ANOVA with Fisher’s LSD post-hoc test). (E) Representative images of pSTAT3 in the 
SP layer of saline Il6rafl/fl, MIA Il6rafl/fl, saline Cyp19-Cre+;Il6rafl/fl, and MIA Cyp19-
Cre+;Il6rafl/fl placentas. Scale bar = 100 µm. * p < 0.05, ** p < 0.01, *** p < 0.001 
between groups. Data are presented as mean ± SEM. D: decidua, L: labyrinth, n.s.: not 
significant. 
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Fig. 3. Deletion of placental trophoblast Il6ra prevents MIA-induced acute responses in 
the fetal brain. (A) Fetal brain IL-6 gene expression was measured by qPCR. MIA 
increases Il6 gene expression in the Il6rafl/fl fetal brain, but not in Cyp19-Cre+;Il6rafl/fl 
fetal brain. Il6 gene expression was normalized to β-actin. All groups n = 3 litters (8, 7, 8, 
12 fetal brains were used for Saline Cre-; MIA Cre-; Saline Cre+; MIA Cre+, 
respectively). (MIA: F(1,8) = 8.043, p = 0.0219; Cre: F(1,8) = 0.01323, p = 0.9113; 
MIAxCre: F(1,8) = 4.883, p = 0.0581; Post hoc- Saline v.s. MIA: Cre- p = 0.0073, Cre+ p 
= 0.6696) (Two-way ANOVA with Fisher’s LSD post-hoc test) (B-C) Quantification of 
pSTAT3+ cells in the fetal (B) prepontine hindbrain (PPH) (MIA: F(1,8) = 2.956, p = 
0.1239; Cre: F(1,8) = 9.251, p = 0.0160; MIAxCre: F(1,8) = 15.96, p = 0.0040; Post hoc- 
Saline v.s. MIA: Cre- p = 0.0037, Cre+ p = 0.1463; Cre- v.s. Cre+: Saline p = 0.5192, 
MIA p = 0.0011) and (C) pontine hindbrain (PH) (MIA: F(1,8) = 3.757, p = 0.0886; Cre: 
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F(1,8) = 14.50, p = 0.0052; MIAxCre: F(1,8) = 0.1662, p = 0.6942; Post hoc- Cre- v.s. Cre+: 
Saline p = 0.0429, MIA p = 0.0176). All groups n = 3 litters (6, 7, 3, 6 fetal brains were 
used in Saline Cre-; MIA Cre-; Saline Cre+; MIA Cre+, respectively) (Two-way ANOVA 
with Fisher’s LSD post-hoc test). pSTAT3+ cells are more abundant in MIA-induced in 
Il6rafl/fl fetal PPH compared to saline controls. Reduction of pSTAT3+ cells in the fetal 
PPH is observed in Cyp19-Cre+;Il6rafl/fl compared to Il6rafl/fl fetus following MIA. (D-E) 
Elevation of pSTAT3 in MIA fetal hindbrain is prevented when knockout of Il6ra in 
plcantal trophoblast. Representative images of pSTAT3 staining in sagittal sections of 
saline Il6rafl/fl, MIA Il6rafl/fl, saline Cyp19-Cre+;Il6rafl/fl and MIA Cyp19-Cre+;Il6rafl/fl 
fetal PPH (D) and PH (E). Scale bar = 200 µm. * p < 0.05, ** p < 0.01 between groups. 
Data are presented as mean ± SEM. n.s.: not significant. 
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Fig. 4. Deletion of placental trophoblast Il6ra prevents cerebellar neuropathology and 
behavioral abnormalities in MIA offspring. (A) Representative images of calbindin and 
parvalbumin immunofluorescence staining in the offspring adult brain. Cerebellar 
Purkinje cells are labeled by calbindin (red) and co-stained for parvalbumin (green). 
Scale bar = 200 µm. Quantification of (B) calbindin+ and (C) parvalbumin+ Purkinje cell 
density at cerebellar lobule VII (Calbindin- MIA: F(1,8) = 24.14, p = 0.0410; Cre: F(1,8) = 
1.392, p = 0.5752; MIAxCre: F(1,8) = 41.85, p = 0.0126; Post hoc- Saline v.s. MIA: Cre- p 
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= 0.0040, Cre+ p = 0.6008; Cre- v.s. Cre+: Saline p = 0.1012, MIA p = 
0.0280)(Parvalbumin- MIA: F(1,8) = 30.45, p = 0.0006; Cre: F(1,8) = 0.1830, p = 0.6801; 
MIAxCre: F(1,8) = 5.403, p = 0.0486; Post hoc- Saline v.s. MIA: Cre- p = 0.0005, Cre+ p 
= 0.0539; Cre- v.s. Cre+: Saline p = 0.2167, MIA p = 0.0875). All groups n = 3 litters (1-
2 offspring per group) (Two-way ANOVA with Fisher’s LSD post-hoc test). * p < 0.05,  
** p < 0.01, *** p < 0.001 between groups (Data are presented as mean ± SEM. ML: 
molecular layer, GCL: granule cell layer, PCL: Purkinje cell layer. n.s.: not significant. 
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Fig. 5. Deletion of placental trophoblast Il6ra prevents behavioral abnormalities in MIA 
offspring. (A-B) Offspring social behavior was assessed by 3 chamber social test. 
Maternal saline treated offspring display social preference, whereas they spend more time 
in the mouse chamber over than object chamber. On the contrary, MIA Il6rafl/fl offspring 
do not have social preference. Deletion of placental IL-6Rα in MIA offspring display 
social preference (A) Mouse v.s. Object: Student’s two-tailed unpaired t test; Chamber 
duration: Saline Cre- t10 = 5.505, p = 0.0003, MIA Cre- t10 = 1.503, p = 0.1637, Saline 
Cre+ t10 = 12.71, p < 0.0001, MIA Cre+ t10 = 6.032, p = 0.0001. (B) Mouse v.s. Object: 
Student’s two-tailed unpaired t test Cup investigation time: Saline Cre- t10 = 4.195, p = 
0.0018, MIA Cre- t10 = 1.081, p = 0.3053, Saline Cre+ t10 = 5.1777, p = 0.0004, MIA 
Cre+ t10 = 4.957, p = 0.0006. All groups n = 6 litters (22, 22, 19, 25 offspring were used 
for Saline Cre-; MIA Cre-; Saline Cre+; MIA Cre+, respectively). (C) 
Stereotypic/repetitive behavior was measured by marble burying test. Increased repetitive 
marble burying behavior is seen in MIA Il6rafl/fl offspring, but abrogated in MIA Cyp19-
Cre+;Il6rafl/fl offspring (MIA: F(1,20) = 0.5537, p = 0.4655; Cre: F(1,8) = 2.156, p = 0.1576; 
MIAxCre: F(1,8) = 10.55, p = 0.0040; Post hoc- Saline v.s. MIA: Cre- p = 0.0105, Cre+ p 
= 0.0919; Cre- v.s. Cre+: Saline p = 0.2226, MIA p = 0.0033)(Two-way ANOVA with 
Fisher’s LSD post-hoc test). All groups n = 6 litters (22, 22, 26, 25 offspring were used 
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for Saline Cre-; MIA Cre-; Saline Cre+; MIA Cre+, respectively). * p < 0.05,  ** p < 0.01, 
*** p < 0.001, **** p < 0.0001 between groups. Data are presented as mean ± SEM. n.s.: 
not significant. 
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Highlights 
• IL-6 downstream signaling is activated in specific regions of fetal hindbrain after 
MIA.  
• Placental IL-6Rα knockout prevents MIA induced inflammatory responses in 
placental-fetal  axis  
• MIA-induced behavioral abnormalities are prevented in placental IL-6Rα 
knockout mice  
• MIA-induced cerebellar neuropathologies are prevented in placental IL-6Rα 
knockout mice  
 
 
